NEW YORK (AP) — Consecutive federal court decisions regarding abortion medication access are pushing this divisive political topic back into the national conversation as midterm elections approach, with control of Congress hanging in the balance during President Donald Trump’s second term.
A federal appeals court decision on Friday limited mail-order access to mifepristone prescriptions, representing the most significant change to federal abortion policy since the Supreme Court’s 2022 ruling that permitted states to implement abortion prohibitions. This medication represents one of the nation’s most frequently used abortion procedures.
The nation’s highest court intervened Monday to temporarily maintain widespread access to the medication while continuing its review of the matter, potentially leading to a ruling with far-reaching implications for both patients and healthcare providers.
While it remains premature to determine how these recent court actions might influence this year’s electoral outcomes, particularly when economic concerns are anticipated to dominate voter priorities, advocates from both camps hope the developments will mobilize supporters.
Organizations supporting abortion access are already developing strategies to engage voters who may be more inclined to support Democratic candidates due to concerns about additional restrictions. Conversely, anti-abortion activists who believe the Republican-controlled federal government has fallen short in banning these medications are cautioning that traditionally reliable Republican voters might abstain from future elections. One prominent anti-abortion leader described the situation as “a five-alarm crisis” for the GOP.
Following the 2022 reversal of Roe v. Wade, multiple states approved constitutional amendments protecting abortion rights, generating unprecedented voter participation that often benefited Democratic candidates in other races.
However, Democratic pollster Celinda Lake suggests the issue had begun losing some influence with voters—not due to diminished Democratic concern, but because many felt the “damage has been done.”
Despite Friday’s ruling being temporarily suspended, it served as a reminder to voters that their access to abortion medication via telehealth services isn’t secure, even in states with protected abortion rights, Lake explained. This situation presents a significant but “horrific” chance to inform voters about what’s at risk in this year’s midterm contests, she noted.
Mini Timmaraju, president and CEO of the abortion rights organization Reproductive Freedom for All, indicated that voter outreach regarding the instability of abortion access will feature prominently in her group’s midterm strategy. This includes reaching out to voters who backed Trump while simultaneously supporting abortion rights in their 2024 state elections.
“The only way for us to really stop this back and forth is to have abortion access be legal in all 50 states,” she stated. “The only way we do that is through federal legislation, which makes the midterm elections even more urgent.”
The Republican coalition faces challenges from an increasingly frustrated segment of abortion opponents who anticipated Trump would deliver on his commitment to serve as the “most pro-life president in history” but claim they haven’t witnessed such action.
The most pressing concern involves a Food and Drug Administration safety evaluation of mifepristone that anti-abortion organizations hope will lead to additional restrictions, including prohibiting its prescription through telehealth services. These groups have pressed FDA commissioner Dr. Marty Makary to expedite the review, while the administration maintains it “is taking care to do this study properly and in the right way.”
Monday saw the anti-abortion organization SBA Pro-Life America intensify its rhetoric, demanding Makary’s dismissal over this matter.
“This is a five-alarm crisis for the pro-life movement and for the GOP,” stated the organization’s president Marjorie Dannenfelser. “The GOP cannot win without its base and simply will not get the enthusiasm that drives turnout without leadership from the top.”
Trump, whose initial presidential term appointments enabled the Supreme Court majority that overturned Roe, has implemented some measures that abortion opponents have applauded, including attempts to deny funding to Planned Parenthood and initiating investigations into states requiring state-regulated insurance plans to include abortion coverage.
Nevertheless, he has frequently attempted to avoid the abortion debate, stating his belief that individual states should decide the matter. The president supported abortion rights publicly before entering politics in 2015, and his wife, Melania Trump, declared her broad support for abortion rights in 2024.
Anti-abortion activists indicate they have no intention of allowing Trump to sidestep this issue for his remaining time in office. Marc Wheat, general counsel for former Vice President Mike Pence’s political advocacy organization Advancing American Freedom, said his group will intensify pressure on the administration. This includes pushing the FDA to quickly release mifepristone-related documents owed to the group through litigation.
“President Trump thinks that pro-life is a loser,” Wheat commented. “He might see that the pro-lifers may not turn out in the numbers that he needs.”
While Trump and the Republican-controlled Congress encounter growing pressure from conservative factions to limit medication abortion access, Republicans nationwide are far from unified on this stance.
Approximately two-thirds of Americans opposed nationwide mifepristone prohibitions, according to a KFF survey conducted in late 2024. Most Democrats and independents rejected such bans, while Republican opinion was more divided.
American perspectives on abortion remain nuanced, with roughly two-thirds of adults believing abortion should remain legal in all or most circumstances, based on AP-NORC polling data. Relatively few Americans think abortion should be prohibited in every situation.
At least one abortion opponent, Americans United for Life CEO John Mize, said his focus remains on gradual progress rather than the comprehensive changes some allies advocate. While he wishes the FDA would accelerate its safety review, he acknowledges that not all Americans share his position.
“I think there is advancement being made in a positive direction,” he said. “While it might not meet the pace that many in the pro-life movement want to see, I think it meets the acceptable place of where we’re at culturally.”
